Helus Pharma has surpassed 86% enrollment in its Phase 3 APPROACH trial for major depressive disorder and priced a US$50 million underwritten offering. The APPROACH study is evaluating HLP003, a novel serotonergic agonist that previously received Breakthrough Therapy Designation from the U.S. FDA, with topline data expected in the fourth quarter of 2026. The company priced 10,309,280 common shares at US$4.85 per share, with the offering expected to close on June 25, 2026, and proceeds will fund advancement of HLP003, the Phase 2 HLP004 program for generalized anxiety disorder, and the preclinical HLP005 candidate for treatment-resistant depression. Interim CEO Eric So stated the enrollment progress underscores execution of the clinical program. Helus Pharma is the commercial operating name of Cybin Inc.
Cybin Inc. Common StockPriced $50M offering to fund pipeline advancement, indicating financial support for clinical programs.